Purification of soluble HLA class I complexes from human serum or plasma deliver high quality immuno peptidomes required for biomarker discovery

Proteomics

Volumn 17, Issue 1-2, 2017, Pages

  Ritz, Danilo ^a   Gloger, Andreas ^b   Neri, Dario ^b   Fugmann, Tim ^a  

^a PHILOCHEM AG   (Switzerland)

^b ETH ZURICH   (Switzerland)

Author keywords

Antigens; Biomarker; Biomedicine; Body fluids; HLA peptidomics; Immunopeptidomics; sHLA

Indexed keywords

BIOLOGICAL MARKER; HLA ANTIGEN CLASS 1; IMMUNOPEPTIDOME; PEPTIDE; UNCLASSIFIED DRUG; HLA ANTIGEN;

ALLELE; AMINO ACID SEQUENCE; ANTIGEN PURIFICATION; ARTICLE; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EXTRACELLULAR SPACE; HLA SYSTEM; HUMAN; MOLECULAR WEIGHT; NORMAL HUMAN; PEPTIDOMICS; PLASMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN STABILITY; RETENTION TIME; SERUM; BLOOD;

BIOMARKERS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; PEPTIDES;

EID: 85007099142     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201600364     Document Type: Article

References (16)

1. Neefjes, J., Jongsma, M. L., Paul, P., Bakke, O., Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat. Rev. Immunol. 2011, 11, 823–836.
2. Campoli, M., Ferrone, S., Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens 2008, 72, 321–334.
3. Puppo, F., Scudeletti, M., Indiveri, F., Ferrone, S., Serum HLA class I antigens: markers and modulators of an immune response? Immunol. Today 1995, 16, 124–127.
4. Tabayoyong, W. B., Zavazava, N., Soluble HLA revisited. Leukemia Res. 2007, 31, 121–125.
5. Bassani-Sternberg, M., Barnea, E., Beer, I., Avivi, I. et�al., Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 18769–18776.
6. Bassani-Sternberg, M., Pletscher-Frankild, S., Jensen, L. J., Mann, M., Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol. Cell. Proteomics 2015, 14, 658–673.
7. Ritz, D., Gloger, A., Weide, B., Garbe, C. et�al., High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' sera. Proteomics 2016, 16, 1570–1580.
8. Rapin, N., Hoof, I., Lund, O., Nielsen, M., The MHC motif viewer: a visualization tool for MHC binding motifs. Current Protocols in Immunology 2010, 88:18.17, 18.17.1–18.17.13.
9. Nielsen, M., Lundegaard, C., Blicher, T., Lamberth, K. et�al., NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLos One 2007, 2, e796.
10. Gloger, A., Ritz, D., Fugmann, T., Neri, D., Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes. Cancer Immuno. Immunother. 2016, 65, 1377–1393.
11. Mohammed, F., Cobbold, M., Zarling, A. L., Salim, M. et�al., Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat. Immunol. 2008, 9, 1236–1243.
12. Rasmussen, M., Fenoy, E., Harndahl, M., Kristensen, A. B. et�al., Pan-specific prediction of peptide-MHC class I complex stability, a correlate of T cell immunogenicity. J. Immunol. 2016, 197, 1517–1524.
13. Anderson, N. L., Anderson, N. G., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845–867.
14. Verdegaal, E. M., de Miranda, N. F., Visser, M., Harryvan, T. et�al., Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 2016, 536, 91–95.
15. Bowness, P., HLA-B27. Annu. Rev. Immunol. 2015, 33, 29–48.
16. Andreatta, M., Lund, O., Nielsen, M., Simultaneous alignment and clustering of peptide data using a Gibbs sampling approach. Bioinformatics 2013, 29, 8–14.